



Mailing Address:
ADAP Advocacy
PO Box 846
Nags Head, NC 27959

Office Address:
1630 Connecticut Ave, NW
Suite 500
Washington, DC 20009

CEO:
Brandon M. Macsata
Washington, D.C.

Board of Directors:

Co-Chair
Guy Anthony
Brooklyn, NY

Co-Chair
Wanda Brendle, Moss, R.N.
Winston-Salem, NC

Secretary
Lisa Johnson-Lett
Birmingham, AL

Treasurer
Robert "Bobby" L. Dorsey, Esq.
La Plata, MD

Erin Darling, Esq.
Washington, DC

Lyne Fortin, B.Pharm, MBA
Montreal, Canada

Maria Mejia
Tamarac, FL

Shabbir Imber Safdar
San Francisco, CA

Jennifer Vaughan
Watsonville, CA

Marcus A. Wilson
Orlando, FL

Directors Emeritus:
Michelle Anderson
William Arnold – *in memoriam*
John D. Kemp, Esq.
Gary Rose – *in memoriam*
Joyce Turner Keller
Rani Whitfield, M.D.

adapadvocacy.org

ADAP Advocacy Applauds Gilead Sciences for Protecting State AIDS Drug Assistance Programs

Prices for HIV Medicines Avoid Increase, Thanks to Patient Advocacy

For Immediate Release:
October 21, 2025

Media Contact:
info@adapadvocacy.org

WASHINGTON, D.C. – ADAP Advocacy applauded Gilead Sciences for its decision to cease any planned price increases on HIV medicines under the State AIDS Drug Assistance Programs, or ADAPs. Negotiations led by the AIDS Crisis Task Force—coupled with direct communications by numerous patient advocacy organizations, including ADAP Advocacy—helped the company better understand that any proposed price increase would have been detrimental to the program and the patients it serves.

Brandon M. Macsata, CEO of ADAP Advocacy, stated, “**Gilead Sciences has long served as one of the major pillars of HIV research, testing, and treatment across the globe, providing significant levels of funding to support investigative drug trials, decrease infection rates, and improve the quality of life for patients living with this chronic condition. Over the past twenty years, Gilead Sciences has consistently stepped in to address domestic financial challenges created by federal and state government funding shortfalls, providing *both* deep discounts on medications and additional direct funding to HIV prevention and treatment programs. We do *not* speak lightly when we say that, without Gilead Sciences’ consistent support, the treatment landscape in the United States would be significantly worse than it currently is.**”

Macsata further stated that patient advocates and their valued relationships with Gilead Sciences made this decision possible, not the typical pharma-bashing jargon or grandstanding by politicians seeking the next 30-second sound bite.

To learn more about ADAP Advocacy, AIDS Drug Assistance Programs, or the decision by Gilead Sciences, please email info@adapadvocacy.org.

#####

About ADAP Advocacy: ADAP Advocacy’s mission is to promote and enhance the AIDS Drug Assistance Programs (ADAPs) and improve access to care for persons living with HIV/AIDS. ADAP Advocacy works with advocates, community, health care, government, patients, pharmaceutical companies, and other stakeholders to raise awareness, offer patient educational programs, and foster greater community collaboration.